These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 28766236

  • 1. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.
    Matharu M, Halker R, Pozo-Rosich P, DeGryse R, Manack Adams A, Aurora SK.
    J Headache Pain; 2017 Dec; 18(1):78. PubMed ID: 28766236
    [Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

  • 3. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 4. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD.
    Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.
    Lipton RB, Rosen NL, Ailani J, DeGryse RE, Gillard PJ, Varon SF.
    Cephalalgia; 2016 Aug 15; 36(9):899-908. PubMed ID: 27288354
    [Abstract] [Full Text] [Related]

  • 11. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
    Dodick DW, Silberstein SD, Lipton RB, DeGryse RE, Adams AM, Diener HC.
    Cephalalgia; 2019 Jul 15; 39(8):945-956. PubMed ID: 31112399
    [Abstract] [Full Text] [Related]

  • 12. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
    Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group.
    Cephalalgia; 2010 Jul 15; 30(7):804-14. PubMed ID: 20647171
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
    Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A.
    J Headache Pain; 2018 Feb 05; 19(1):13. PubMed ID: 29404713
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis.
    Diener HC, Dodick DW, Lipton RB, Manack Adams A, DeGryse RE, Silberstein SD.
    Pain Ther; 2020 Dec 05; 9(2):683-694. PubMed ID: 33026631
    [Abstract] [Full Text] [Related]

  • 17. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F, Gaul C, García-Moncó JC, Sommer K, Martelletti P, REPOSE Principal Investigators.
    J Headache Pain; 2019 Mar 07; 20(1):26. PubMed ID: 30845917
    [Abstract] [Full Text] [Related]

  • 18. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
    Santoro A, Fontana A, Miscio AM, Zarrelli MM, Copetti M, Leone MA.
    Neurol Sci; 2017 Oct 07; 38(10):1779-1789. PubMed ID: 28726049
    [Abstract] [Full Text] [Related]

  • 19. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
    Frampton JE.
    Drugs; 2012 Apr 16; 72(6):825-45. PubMed ID: 22468643
    [Abstract] [Full Text] [Related]

  • 20. Development of onabotulinumtoxinA for chronic migraine.
    Whitcup SM, Turkel CC, DeGryse RE, Brin MF.
    Ann N Y Acad Sci; 2014 Nov 16; 1329():67-80. PubMed ID: 25399521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.